824 filings
Page 3 of 42
8-K
5hd87
15 Sep 23
Changes in Registrant's Certifying Accountant
4:05pm
UPLOAD
5u9j sxggm
12 Sep 23
Letter from SEC
12:00am
NT 10-Q
0jinst
14 Aug 23
Notice of late quarterly filing
4:09pm
ARS
qsq8fya2 ggiv
7 Aug 23
Annual report to shareholders
4:09pm
DEFA14A
i1k1cs4wxal2gj 9f
7 Aug 23
Additional proxy soliciting materials
4:07pm
8-K
vlpwy wgm08
7 Jul 23
Departure of Directors or Certain Officers
4:05pm
8-K
a534c
23 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
m638ea7 f86syx
26 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
g44cfa
9 May 23
Soligenix Announces Pricing of $8.5 Million Public Offering
4:15pm
EFFECT
24dn9kfog5ya0b
8 May 23
Notice of effectiveness
12:15am
424B4
1by v0qck26
5 May 23
Prospectus supplement with pricing info
6:43pm
CORRESP
poksv3s1uo5azg4fbx6
4 May 23
Correspondence with SEC
12:00am
8-K
jfyj 5utg1x
3 May 23
Strengthens regulatory and orphan drug development expertise
5:00pm
8-K
xiyh2eedwz1v
1 May 23
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease
7:45am